reviral company logo

ReViral – Fusion Inhibitors for RSV

ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.

  • Respiratory Syncytial Virus (RSV) represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity.
  • Reviral is developing fusion inhibitor of RSV which is a highly potent, novel small molecule
  • In clinical trial in H2/2016

Upcoming Events

9-13 January 2017
The J.P. Morgan 35th Annual Healthcare Conference
San Francisco, CA, USA

20-22 March 2017
BIO Europe Spring meeting

Barcelona, Spain



Latest News
Oct 3, 2016
ReViral Announces Appointment of New Chief Executive Officer
London, UK, 3rd October 2016 / ReViral Ltd, a biotechnology company, aiming...
Jun 17, 2016
New laboratory facilities for ReViral
Refurbishment work is now completed at the North East Technology Park (NETPark) in Sedgefield...
Terms & Conditions
Privacy Policy
© Copyright ReViral 2016